Arbutus Biopharma (ABUS) Profit After Tax (2013 - 2026)

Arbutus Biopharma has disclosed Profit After Tax across 14 years of filings, most recently posting $169.7 million for Q1 2026.

• Profit After Tax for Q1 2026 came in at $169.7 million, up 791.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $160.7 million (up 309.9% YoY), and the FY2025 annual result was -$33.5 million, up 52.09% from the prior year.
• Profit After Tax came in at $169.7 million for Q1 2026 at Arbutus Biopharma, up from -$3.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $169.7 million in Q1 2026 to a low of -$24.5 million in Q1 2025.
• The 5-year median for Profit After Tax is -$17.1 million (2023), against an average of -$4.5 million.
• Across the five-year window, Profit After Tax sank 37.21% in 2025 and surged 791.9% in 2026, its largest moves.
• Arbutus Biopharma's Profit After Tax stood at -$21.9 million in 2022, then advanced by 11.95% to -$19.3 million in 2023, then jumped by 35.11% to -$12.5 million in 2024, then surged by 70.03% to -$3.8 million in 2025, then surged by 4617.97% to $169.7 million in 2026.
• The last three Profit After Tax figures came in at $169.7 million (Q1 2026), -$3.8 million (Q4 2025), and -$7.7 million (Q3 2025), per Business Quant data.